NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free XNCR Stock Alerts $24.11 +0.48 (+2.03%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$24.01▼$25.0950-Day Range$18.21▼$26.5252-Week Range$16.49▼$28.96Volume437,491 shsAverage Volume705,960 shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Xencor alerts: Email Address Xencor MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside49.3% Upside$36.00 Price TargetShort InterestBearish10.09% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment0.86Based on 5 Articles This WeekInsider TradingSelling Shares$2.15 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.25) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector811th out of 5,430 stocksPharmaceutical Preparations Industry271st out of 2,526 stocks 4.4 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXencor has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.09% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Xencor has recently increased by 4.71%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 3.3 News and Social Media Coverage News SentimentXencor has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Xencor this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Xencor to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,152,417.00 in company stock.Percentage Held by InsidersOnly 4.97% of the stock of Xencor is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.25) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -11.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -11.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Xencor Stock (NASDAQ:XNCR)Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More XNCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XNCR Stock News HeadlinesMay 4, 2024 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsMay 3, 2024 | finance.yahoo.comInsider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells SharesMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 16, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For XencorApril 11, 2024 | uk.investing.comXencor names Bart Cornelissen as new CFOApril 10, 2024 | markets.businessinsider.comXencor Appoints Bart Cornelissen As CFOApril 9, 2024 | marketwatch.comXencor Names Bart Cornelissen Chief Financial OfficerApril 9, 2024 | finance.yahoo.comXencor Appoints Bart Cornelissen as Chief Financial OfficerMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 9, 2024 | businesswire.comXencor Appoints Bart Cornelissen as Chief Financial OfficerMarch 16, 2024 | finance.yahoo.comXNCR Apr 2024 30.000 callMarch 9, 2024 | finance.yahoo.comXNCR May 2024 22.500 putMarch 7, 2024 | finance.yahoo.comInsider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)March 1, 2024 | markets.businessinsider.comXencor’s Strategic Focus and Pipeline Progress Affirm Buy RatingMarch 1, 2024 | msn.comPiper Sandler Downgrades Xencor (XNCR)February 29, 2024 | morningstar.comXencor Inc XNCRFebruary 29, 2024 | finance.yahoo.comXencor Full Year 2023 Earnings: Misses ExpectationsFebruary 28, 2024 | seekingalpha.comXencor Q4 2023 Earnings PreviewFebruary 28, 2024 | finance.yahoo.comXencor to Present at Upcoming Investor ConferencesFebruary 28, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On XencorFebruary 28, 2024 | msn.comXencor slips as Piper cuts citing patient death in cancer studyFebruary 28, 2024 | markets.businessinsider.comXencor (XNCR) Gets a Buy from TD CowenFebruary 28, 2024 | finance.yahoo.comXencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | sfgate.comXencor: Q4 Earnings SnapshotFebruary 27, 2024 | finance.yahoo.comXencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023February 27, 2024 | businesswire.comXencor Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | markets.businessinsider.comXencor earnings preview: what Wall Street is expectingSee More Headlines Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/03/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$50.00 Low Stock Price Target$24.00 Potential Upside/Downside+49.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,090,000.00 Net Margins-74.90% Pretax Margin-71.55% Return on Equity-18.67% Return on Assets-15.23% Debt Debt-to-Equity Ratio0.02 Current Ratio7.36 Quick Ratio7.36 Sales & Book Value Annual Sales$168.34 million Price / Sales8.83 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book2.19Miscellaneous Outstanding Shares61,650,000Free Float58,583,000Market Cap$1.49 billion OptionableOptionable Beta0.77 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Bassil I. Dahiyat Ph.D. (Age 54)Co-Founder, CEO, President & Director Comp: $1.07MDr. John R. Desjarlais Ph.D. (Age 60)Executive VP of Research & Chief Scientific Officer Comp: $748.65kMs. Celia E. Eckert J.D. (Age 51)Senior VP, General Counsel & Corporate Secretary Comp: $641.85kDr. Nancy Valente M.D. (Age 65)Executive VP & Chief Development Officer Comp: $797.68kMr. Bart Jan CornelissenSenior VP & CFOMr. Charles LilesAssociate Director and Head of Corporate Communications & Investor RelationsMs. Jennifer SandozSenior VIce President of Human ResourcesDr. Jeremy Grunstein Ph.D.Senior Vice President of Business DevelopmentMr. Kirk Rosemark RAC (Age 59)Senior Vice President of Regulatory Affairs & Quality Assurance Mr. Eric P. KowackSenior Vice President of Program Leadership & Alliance ManagementMore ExecutivesKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAGyre TherapeuticsNASDAQ:GYREVerona PharmaNASDAQ:VRNALigand PharmaceuticalsNASDAQ:LGNDGemini TherapeuticsNASDAQ:GMTXView All CompetitorsInsiders & InstitutionsMutual of America Capital Management LLCSold 6,829 shares on 5/2/2024Ownership: 0.150%BNP Paribas Financial MarketsSold 36,693 shares on 5/1/2024Ownership: 0.074%Mirae Asset Global Investments Co. Ltd.Bought 3,144 shares on 5/1/2024Ownership: 0.055%Baillie Gifford & Co.Sold 8,219 shares on 5/1/2024Ownership: 0.037%China Universal Asset Management Co. Ltd.Bought 4,714 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions XNCR Stock Analysis - Frequently Asked Questions Should I buy or sell Xencor stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks. What is Xencor's stock price target for 2024? 9 Wall Street analysts have issued 1 year target prices for Xencor's shares. Their XNCR share price targets range from $24.00 to $50.00. On average, they expect the company's stock price to reach $36.00 in the next year. This suggests a possible upside of 49.3% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts. How have XNCR shares performed in 2024? Xencor's stock was trading at $21.23 at the beginning of the year. Since then, XNCR shares have increased by 13.6% and is now trading at $24.11. View the best growth stocks for 2024 here. When is Xencor's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our XNCR earnings forecast. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of $0.36 by $0.67. The biopharmaceutical company earned $44.70 million during the quarter, compared to analysts' expectations of $77.63 million. Xencor had a negative trailing twelve-month return on equity of 18.67% and a negative net margin of 74.90%. The company's quarterly revenue was up 106.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.20) EPS. What ETFs hold Xencor's stock? ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).iShares Genomics Immunology and Healthcare ETF (IDNA). What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). Who are Xencor's major shareholders? Xencor's stock is owned by many different institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (0.53%), Mutual of America Capital Management LLC (0.15%), BNP Paribas Financial Markets (0.07%), Mirae Asset Global Investments Co. Ltd. (0.06%), Baillie Gifford & Co. (0.04%) and Yousif Capital Management LLC (0.04%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais and Kurt A Gustafson. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XNCR) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe Gold Grab of the CenturyColonial Metals4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
